InSilico Medicine Cayman TopCo Company Description

InSilico Medicine Cayman TopCo engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms.

The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services.

Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and other therapeutic areas.

The company is also involved in research and development collaboration, software solutions, business development, new drug discovery, and holding company businesses.

The company has a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. for the development of oligonucleotide therapeutics.

It operates in Hong Kong, the United States, the United Kingdom, Kingdom of Saudi Arabia, Japan, Denmark, the United Arab Emirates, Korea, Mainland China, Germany, Switzerland, Taiwan, and internationally.

The company was founded in 2014 and is based in New Territories, Hong Kong.

InSilico Medicine Cayman TopCo

Country	Cayman Islands
Founded	2014
Industry	Software - Infrastructure
Sector	Technology
Employees	317

Contact Details

Address: Building 8W, Phase 2 Hong Kong Hong Kong
Phone	852 1626 5937 957
Website	insilico.com

Stock Details

Ticker Symbol	3696
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	7372

Key Executives

Name	Position
Dr. Feng Ren Ph.D.	CO-Chief Executive Officer, Chief Scientific Officer, Longevity Board Member and Executive Director
Dr. Aleksandrs Zhavoronkov Ph.D.	Founder, Chief Executive Officer, Chief Business Officer, Longevity Board Member and Chairman of the Board
Peng Dai	Vice President and Head of Finance
Aleksandr Aliper Ph.D.	President
Dr. Xiao Ding	Head of Chemistry
Dr. Man Zhang	Head of Biology
Leung Kwan Wai	Company Secretary